本帖最后由 老马 于 2012-1-13 21:20 编辑
+ ~& ^& @ ?: x3 D1 L/ C+ {# q: D3 e8 _. X1 [+ M+ [+ o4 n
爱必妥和阿瓦斯丁的比较
2 b" E- x8 T# L3 o P
; V/ Q- _1 |% ahttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
' W' }4 Q h9 l; U8 r& }
" X5 F; ^4 w% W+ Q( N+ C
: s5 f! S( D# ~* f8 c) w+ w
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/4 F# _% u0 n" m0 f) e* |6 v
==================================================
2 @: h% f, H w! COverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)# [- c& I2 W; T5 q
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.% H2 z) `, I2 t
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.1 |) U4 U. J) Q t) u
|
显身卡
